AIMS: The purpose was to analyse the characteristics, treatment, recurrences and survival of very young women with breast cancer. METHODS: 212 female breast cancer patients ≤35 years old were treated during 1997-2007. The median follow-up time was 78 months. RESULTS: 117 patients had lymph node metastases and 14 distant metastases at diagnosis. 81 (38%) tumours were hormone receptor negative and 130 (65%) grade 3. HER2 positivity was seen in 47 (34%) and triple negativity in 35 (26%) of the 137 tumours with known HER2 status. 140 women were treated with mastectomy and 68 with breast conserving surgery. 163 patients received postoperative radiotherapy, 175 adjuvant chemotherapy, 95 endocrine therapy and 18 trastuzumab. 63 patients experienced a recurrence, of which 20 had only a locoregional recurrence. 10 (15%) of the women with breast conserving surgery experienced ipsilateral breast tumour recurrence while ipsilateral thoracic wall recurrence was seen in 8 patients (6%) after mastectomy. Seven of these eight patients did not receive postmastectomy radiotherapy. DFI was shorter in patients with hormone receptor positive tumours. At the end of follow-up 44 women had died. The 5-year OS was 80%. CONCLUSIONS: The 5-year OS for young women has become better but is still lower than for all breast cancer patients. DFI was shorter in patients with hormone receptor positive disease. Locoregional recurrences were seen more often after breast conserving surgery.
AIMS: The purpose was to analyse the characteristics, treatment, recurrences and survival of very young women with breast cancer. METHODS: 212 female breast cancerpatients ≤35 years old were treated during 1997-2007. The median follow-up time was 78 months. RESULTS: 117 patients had lymph node metastases and 14 distant metastases at diagnosis. 81 (38%) tumours were hormone receptor negative and 130 (65%) grade 3. HER2 positivity was seen in 47 (34%) and triple negativity in 35 (26%) of the 137 tumours with known HER2 status. 140 women were treated with mastectomy and 68 with breast conserving surgery. 163 patients received postoperative radiotherapy, 175 adjuvant chemotherapy, 95 endocrine therapy and 18 trastuzumab. 63 patients experienced a recurrence, of which 20 had only a locoregional recurrence. 10 (15%) of the women with breast conserving surgery experienced ipsilateral breast tumour recurrence while ipsilateral thoracic wall recurrence was seen in 8 patients (6%) after mastectomy. Seven of these eight patients did not receive postmastectomy radiotherapy. DFI was shorter in patients with hormone receptor positive tumours. At the end of follow-up 44 women had died. The 5-year OS was 80%. CONCLUSIONS: The 5-year OS for young women has become better but is still lower than for all breast cancerpatients. DFI was shorter in patients with hormone receptor positive disease. Locoregional recurrences were seen more often after breast conserving surgery.
Authors: Harindra Jayasekara; Robert J MacInnis; James A Chamberlain; Gillian S Dite; Nicole M Leoce; James G Dowty; Adrian Bickerstaffe; Aung Ko Win; Roger L Milne; Graham G Giles; Mary Beth Terry; Diana M Eccles; Melissa C Southey; John L Hopper Journal: Int J Cancer Date: 2019-03-05 Impact factor: 7.396
Authors: Mustafa Emiroğlu; Cem Karaali; İsmail Sert; Semra Salimoğlu; Levent Uğurlu; Süleyman Aksoy; Cengiz Aydın Journal: J Breast Health Date: 2015-07-01
Authors: Joerg Heil; Valerie Fuchs; Michael Golatta; Sarah Schott; Markus Wallwiener; Christoph Domschke; Peter Sinn; Michael P Lux; Christof Sohn; Florian Schütz Journal: Breast Care (Basel) Date: 2012-10 Impact factor: 2.860
Authors: Omar Farouk; Mohamed A Ebrahim; Ahmad Senbel; Ziad Emarah; Waleed Abozeed; Mohamed O Seisa; Summer Mackisack; Salah Abdel Jalil; Safaa Abdelhady Journal: Breast Cancer (Dove Med Press) Date: 2016-04-05
Authors: Annelie Augustinsson; Martin P Nilsson; Carolina Ellberg; Ulf Kristoffersson; Håkan Olsson; Hans Ehrencrona Journal: Breast Cancer Res Treat Date: 2021-09-16 Impact factor: 4.872